CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2014 MASCC/ISOO International Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Keefe on the Role of Supportive Care in Personalized Medicine
Dr. Rapoport on Rolapitant for the Prevention of CINV
Declan Walsh, MSc, FACP, FRCP, on the Under-Diagnosis of Malnutrition
Oncology Conference Articles
Aprepitant Yields Significant Benefits for the Prevention of CINV in Children
Aprepitant is significantly more effective than a comparator placebo-added regimen in preventing CINV in children, with benefits seen across all phases of treatment.
Enobosarm May Prevent Cancer-Induced Muscle Wasting in NSCLC
Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.
Two Phase III Trials Find Rolapitant Effective, Well-Tolerated for Preventing CINV
A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.
Single-Dose of Dexamethasone Adequate With Palonosetron for Controlling CINV
Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.
Netupitant-Palonosetron Combination Shows Continued Superiority Over Palonosetron for CINV
A treatment intended to control chemotherapy-induced nausea and vomiting that combines netupitant and palonosetron demonstrated superior activity in complete response rates over oral palonosetron monotherapy.
Aprepitant- and Metoclopramide-Based Regimens Demonstrate Similar Efficacy in Preventing Delayed Cisplatin-Induced Emesis
For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.
FDA Approvals in Pediatric ALL and PNH, Japanese Approves Pembrolizumab in 5 Indications, and More
Treatment Goals in Refractory mCRC
FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices
FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma
MyDRUG Evaluates Targeted Agents in Multiple Myeloma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.